论文部分内容阅读
观察沙利度胺对慢性乙型肝炎(CHB)血清细胞因子和肝功能的影响,以评价本药在CHB中的治疗价值。62例患者分2组观察,研究组29例,在一般保肝治疗基础上加用沙利度胺50mg,bid口服,连用1月;对照组33例,给予一般保肝药物治疗。结果发现CHB患者血清TNFα、IFNγ基础值显著高于健康人水平,经沙利度胺治疗后血清TNFα和IFNγ逐渐下降,IFNγ/IL-4及IFNγ/IL-10比值有升高倾向,而对照组变化不大;沙利度胺组临床症状改善较快,退黄时间和转氨酶下降速度与对照组相近。由此认为沙利度胺能调节Th1/Th2细胞因子的平衡,对病毒性肝炎有潜在的治疗价值。
The effects of thalidomide on serum cytokines and liver function in patients with chronic hepatitis B (CHB) were observed to evaluate the therapeutic value of this drug in CHB. Sixty-two patients were divided into two groups. The study group consisted of 29 cases. Thalidomide 50 mg and bid were administered orally on the basis of general liver protection treatment for 1 month. The control group received 33 cases of generalized hepatoprotective drugs. The results showed that the basal levels of serum TNFα and IFNγ in CHB patients were significantly higher than those in healthy people. The serum levels of TNFα and IFNγ decreased gradually after treatment with thalidomide, and the ratios of IFNγ / IL-4 and IFNγ / IL-10 tended to increase. Group changed little; thalidomide group clinical symptoms improved rapidly, anti-yellowing time and aminotransferase descent speed and control group similar. Therefore, thalidomide can regulate the balance of Th1 / Th2 cytokines and has potential therapeutic value for viral hepatitis.